Pernix Therapeutics (PTX) Receives Two U.S. Patents Related to Zohydro ER with BeadTek
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/20/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Jabil falls after placing CEO on paid leave amid internal investigation
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- NVIDIA (NVDA) Shares Extend Drop To 10%, Erasing $212 Billion In Value - Bloomberg
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Pernix Therapeutics Announces the Issuance of Two New Orange Book Listed Patents for Zohydro® ER with BeadTek™
September 14, 2016 7:00 AM EDTMORRISTOWN, N.J., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office has issued U.S. Patent Numbers 9,421,200 (200 patent) and 9,433,619 (619 patent), covering important safety information related to dosing patients with Zohydro® ER with BeadTek. These patents, in addition to recently issued U.S. Patent Numbers 9,265,760 (760 patent), 9,326,982 (982 patent), 9,333,201 (201 patent) and 9,339,499 (499 patent), are broadly directed to methods of dosing patients with mild or moderate hepatic impairment with hydrocodone.  The 760, 982, 201, 499, 200, and 619 patents expire on July 25, 2033.
The 200 and 619 patents, solely owned by Pernix, further strengthen our... More
